Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

A miRNAs profile evolution of triple negative breast cancer cells in the presence of a possible adjuvant therapy and senescence inducer.

Lajos R, Braicu C, Jurj A, Chira S, Cojocneanu-Petric R, Pileczki V, Berindan-Neagoe I.

J BUON. 2018 May-Jun;23(3):692-705.

PMID:
30003739
2.

The foundation of personalized medicine is the establishment of biobanks and their standardization.

Policiuc L, Buse M, Gulei D, Andreea Zimta A, Braicu C, Iulia Irimie A, Berindan-Neagoe I.

J BUON. 2018 May-Jun;23(3):550-560.

PMID:
30003718
3.

In Vitro Transcriptome Response to a Mixture of Lactobacilli Strains in Intestinal Porcine Epithelial Cell Line.

Taranu I, Marin DE, Braicu C, Pistol GC, Sorescu I, Pruteanu LL, Berindan Neagoe I, Vodnar DC.

Int J Mol Sci. 2018 Jun 30;19(7). pii: E1923. doi: 10.3390/ijms19071923.

4.

Incognito: Are Microchimeric Fetal Stem Cells that Cross Placental Barrier Real Emissaries of Peace?

Cismaru CA, Pop L, Berindan-Neagoe I.

Stem Cell Rev. 2018 Jun 15. doi: 10.1007/s12015-018-9834-9. [Epub ahead of print] Review.

PMID:
29948753
5.

RNA interference: new mechanistic and biochemical insights with application in oral cancer therapy.

Buduru S, Zimta AA, Ciocan C, Braicu C, Dudea D, Irimie AI, Berindan-Neagoe I.

Int J Nanomedicine. 2018 Jun 8;13:3397-3409. doi: 10.2147/IJN.S167383. eCollection 2018. Review.

6.

Developments in toxicogenomics: understanding and predicting compound-induced toxicity from gene expression data.

Alexander-Dann B, Pruteanu LL, Oerton E, Sharma N, Berindan-Neagoe I, Módos D, Bender A.

Mol Omics. 2018 Jun 19. doi: 10.1039/c8mo00042e. [Epub ahead of print] Review.

PMID:
29917034
7.

Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches.

Tomuleasa C, Selicean C, Cismas S, Jurj A, Marian M, Dima D, Pasca S, Petrushev B, Moisoiu V, Micu WT, Vischer A, Arifeen K, Selicean S, Zdrenghea M, Bumbea H, Tanase A, Grewal R, Pop L, Aanei C, Berindan-Neagoe I.

Crit Rev Clin Lab Sci. 2018 Aug;55(5):329-345. doi: 10.1080/10408363.2018.1463508. Epub 2018 May 25.

PMID:
29801428
8.

Decoding the Emerging Patterns Exhibited in Non-coding RNAs Characteristic of Lung Cancer with Regard to their Clinical Significance.

Sonea L, Buse M, Gulei D, Onaciu A, Simon I, Braicu C, Berindan-Neagoe I.

Curr Genomics. 2018 May;19(4):258-278. doi: 10.2174/1389202918666171005100124.

PMID:
29755289
9.

The role of the pathology department in the preanalytical phase of molecular analyses.

Susman S, Berindan-Neagoe I, Petrushev B, Pirlog R, Florian IS, Mihu CM, Berce C, Craciun L, Grewal R, Tomuleasa C.

Cancer Manag Res. 2018 Apr 12;10:745-753. doi: 10.2147/CMAR.S150851. eCollection 2018.

10.

Genetically enhanced T lymphocytes and the intensive care unit.

Tat T, Li H, Constantinescu CS, Onaciu A, Chira S, Osan C, Pasca S, Petrushev B, Moisoiu V, Micu WT, Berce C, Tranca S, Dima D, Berindan-Neagoe I, Shen J, Tomuleasa C, Qian L.

Oncotarget. 2018 Mar 27;9(23):16557-16572. doi: 10.18632/oncotarget.24637. eCollection 2018 Mar 27. Review.

11.

Comparison of two models of inflammatory bowel disease in rats.

Catana CS, Magdas C, Tabaran FA, Crăciun EC, Deak G, Magdaş VA, Cozma V, Gherman CM, Berindan-Neagoe I, Dumitraşcu DL.

Adv Clin Exp Med. 2018 May;27(5):599-607. doi: 10.17219/acem/69134.

12.

Natural products with anti-aging potential: Affected targets and molecular mechanisms.

Cătană CS, Atanasov AG, Berindan-Neagoe I.

Biotechnol Adv. 2018 Mar 27. pii: S0734-9750(18)30063-6. doi: 10.1016/j.biotechadv.2018.03.012. [Epub ahead of print] Review.

PMID:
29597027
13.

Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations.

Shah MY, Ferracin M, Pileczki V, Chen B, Redis R, Fabris L, Zhang X, Ivan C, Shimizu M, Rodriguez-Aguayo C, Dragomir M, Van Roosbroeck K, Almeida MI, Ciccone M, Nedelcu D, Cortez MA, Manshouri T, Calin S, Muftuoglu M, Banerjee PP, Badiwi MH, Parker-Thornburg J, Multani A, Welsh JW, Estecio MR, Ling H, Tomuleasa C, Dima D, Yang H, Alvarez H, You MJ, Radovich M, Shpall E, Fabbri M, Rezvani K, Girnita L, Berindan-Neagoe I, Maitra A, Verstovsek S, Fodde R, Bueso-Ramos C, Gagea M, Manero GG, Calin GA.

Genome Res. 2018 Apr;28(4):432-447. doi: 10.1101/gr.225128.117. Epub 2018 Mar 22.

PMID:
29567676
14.

Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.

Tomuleasa C, Fuji S, Berce C, Onaciu A, Chira S, Petrushev B, Micu WT, Moisoiu V, Osan C, Constantinescu C, Pasca S, Jurj A, Pop L, Berindan-Neagoe I, Dima D, Kitano S.

Front Immunol. 2018 Feb 19;9:239. doi: 10.3389/fimmu.2018.00239. eCollection 2018. Review.

15.

Current Insights into Oral Cancer Epigenetics.

Irimie AI, Ciocan C, Gulei D, Mehterov N, Atanasov AG, Dudea D, Berindan-Neagoe I.

Int J Mol Sci. 2018 Feb 27;19(3). pii: E670. doi: 10.3390/ijms19030670. Review.

16.

The Unforeseen Non-Coding RNAs in Head and Neck Cancer.

Irimie AI, Zimta AA, Ciocan C, Mehterov N, Dudea D, Braicu C, Berindan-Neagoe I.

Genes (Basel). 2018 Mar 1;9(3). pii: E134. doi: 10.3390/genes9030134. Review.

17.

Restoring the p53 'Guardian' Phenotype in p53-Deficient Tumor Cells with CRISPR/Cas9.

Chira S, Gulei D, Hajitou A, Berindan-Neagoe I.

Trends Biotechnol. 2018 Jul;36(7):653-660. doi: 10.1016/j.tibtech.2018.01.014. Epub 2018 Feb 22. Review.

PMID:
29478674
18.

Implications of dietary ω-3 and ω-6 polyunsaturated fatty acids in breast cancer.

Zanoaga O, Jurj A, Raduly L, Cojocneanu-Petric R, Fuentes-Mattei E, Wu O, Braicu C, Gherman CD, Berindan-Neagoe I.

Exp Ther Med. 2018 Feb;15(2):1167-1176. doi: 10.3892/etm.2017.5515. Epub 2017 Nov 16.

19.

Protein dysregulation in graft versus host disease.

Qian L, Dima D, Berce C, Liu Y, Rus I, Raduly LZ, Liu Y, Petrushev B, Berindan-Neagoe I, Irimie A, Tanase A, Jurj A, Shen J, Tomuleasa C.

Oncotarget. 2017 Dec 15;9(1):1483-1491. doi: 10.18632/oncotarget.23276. eCollection 2018 Jan 2. Review.

20.

Exosomes-Small Players, Big Sound.

Gulei D, Irimie AI, Cojocneanu-Petric R, Schultze JL, Berindan-Neagoe I.

Bioconjug Chem. 2018 Mar 21;29(3):635-648. doi: 10.1021/acs.bioconjchem.8b00003. Epub 2018 Feb 9.

PMID:
29369619
21.

The silent healer: miR-205-5p up-regulation inhibits epithelial to mesenchymal transition in colon cancer cells by indirectly up-regulating E-cadherin expression.

Gulei D, Magdo L, Jurj A, Raduly L, Cojocneanu-Petric R, Moldovan A, Moldovan C, Florea A, Pasca S, Pop LA, Moisoiu V, Budisan L, Pop-Bica C, Ciocan C, Buiga R, Muresan MS, Stiufiuc R, Ionescu C, Berindan-Neagoe I.

Cell Death Dis. 2018 Jan 19;9(2):66. doi: 10.1038/s41419-017-0102-8.

22.

MiR-181 family-specific behavior in different cancers: a meta-analysis view.

Pop-Bica C, Pintea S, Cojocneanu-Petric R, Del Sal G, Piazza S, Wu ZH, Alencar AJ, Lossos IS, Berindan-Neagoe I, Calin GA.

Cancer Metastasis Rev. 2018 Mar;37(1):17-32. doi: 10.1007/s10555-017-9714-9.

PMID:
29327093
23.

CRISPR/Cas9: A Potential Life-Saving Tool. What's next?

Gulei D, Berindan-Neagoe I.

Mol Ther Nucleic Acids. 2017 Dec 15;9:333-336. doi: 10.1016/j.omtn.2017.10.013. Epub 2017 Nov 10. No abstract available.

24.

A Looking-Glass of Non-coding RNAs in oral cancer.

Irimie AI, Braicu C, Sonea L, Zimta AA, Cojocneanu-Petric R, Tonchev K, Mehterov N, Diudea D, Buduru S, Berindan-Neagoe I.

Int J Mol Sci. 2017 Dec 5;18(12). pii: E2620. doi: 10.3390/ijms18122620. Review.

25.

Genetic alterations in sporadic triple negative breast cancer.

Pop LA, Cojocneanu-Petric RM, Pileczki V, Morar-Bolba G, Irimie A, Lazar V, Lombardo C, Paradiso A, Berindan-Neagoe I.

Breast. 2018 Apr;38:30-38. doi: 10.1016/j.breast.2017.11.006. Epub 2017 Dec 5.

PMID:
29202330
26.

Ruxolitinib-conjugated gold nanoparticles for topical administration: An alternative for treating alopecia?

Boca S, Berce C, Jurj A, Petrushev B, Pop L, Gafencu GA, Selicean S, Moisoiu V, Temian D, Micu WT, Astilean S, Braicu C, Tomuleasa C, Berindan-Neagoe I.

Med Hypotheses. 2017 Nov;109:42-45. doi: 10.1016/j.mehy.2017.09.023. Epub 2017 Sep 27.

PMID:
29150291
27.

Therapeutic potential of songorine, a diterpenoid alkaloid of the genus Aconitum.

Khan H, Nabavi SM, Sureda A, Mehterov N, Gulei D, Berindan-Neagoe I, Taniguchi H, Atanasov AG.

Eur J Med Chem. 2018 Jun 10;153:29-33. doi: 10.1016/j.ejmech.2017.10.065. Epub 2017 Nov 11. Review.

PMID:
29133056
28.

Targeting ncRNAs by plant secondary metabolites: The ncRNAs game in the balance towards malignancy inhibition.

Gulei D, Mehterov N, Nabavi SM, Atanasov AG, Berindan-Neagoe I.

Biotechnol Adv. 2017 Nov 10. pii: S0734-9750(17)30131-3. doi: 10.1016/j.biotechadv.2017.11.003. [Epub ahead of print] Review.

PMID:
29129653
29.

Molecular-trapping in Emulsion's Monolayer: A New Strategy for Production and Purification of Bioactive Saponins.

Obasi TC, Moldovan R, Toiu A, Braicu C, Bodoki E, Berindan-Neagoe I, Oniga I, Sandulescu R, Oprean R.

Sci Rep. 2017 Nov 6;7(1):14511. doi: 10.1038/s41598-017-15067-4.

30.

The new era of nanotechnology, an alternative to change cancer treatment.

Jurj A, Braicu C, Pop LA, Tomuleasa C, Gherman CD, Berindan-Neagoe I.

Drug Des Devel Ther. 2017 Sep 27;11:2871-2890. doi: 10.2147/DDDT.S142337. eCollection 2017. Review.

31.

miRNA expression profiling in formalin-fixed paraffin-embedded endometriosis and ovarian cancer samples.

Braicu OL, Budisan L, Buiga R, Jurj A, Achimas-Cadariu P, Pop LA, Braicu C, Irimie A, Berindan-Neagoe I.

Onco Targets Ther. 2017 Aug 28;10:4225-4238. doi: 10.2147/OTT.S137107. eCollection 2017.

32.

Transthoracic ultrasonography for the follow-up of a chronic lymphocytic leukemia patient with chemotherapy-induced immunosuppression prior to allogeneic stem cell transplantation. A case report.

Frinc I, Dima D, Chitic M, Berce C, Berindan-Neagoe I, Tat T, Tanase A, Tomuleasa C, Bojan A.

Med Ultrason. 2017 Mar 14;19(3):330-332. doi: 10.11152/mu-976.

33.

Future trends and emerging issues for nanodelivery systems in oral and oropharyngeal cancer.

Irimie AI, Sonea L, Jurj A, Mehterov N, Zimta AA, Budisan L, Braicu C, Berindan-Neagoe I.

Int J Nanomedicine. 2017 Jun 26;12:4593-4606. doi: 10.2147/IJN.S133219. eCollection 2017. Review.

34.

Understanding the Role of Non-Coding RNAs in Bladder Cancer: From Dark Matter to Valuable Therapeutic Targets.

Pop-Bica C, Gulei D, Cojocneanu-Petric R, Braicu C, Petrut B, Berindan-Neagoe I.

Int J Mol Sci. 2017 Jul 13;18(7). pii: E1514. doi: 10.3390/ijms18071514. Review.

35.

Low level of ochratoxin A affects genome-wide expression in kidney of pig.

Marin DE, Braicu C, Gras MA, Pistol GC, Petric RC, Berindan Neagoe I, Palade M, Taranu I.

Toxicon. 2017 Sep 15;136:67-77. doi: 10.1016/j.toxicon.2017.07.004. Epub 2017 Jul 6.

PMID:
28688805
36.

Nutrigenomics in cancer: Revisiting the effects of natural compounds.

Braicu C, Mehterov N, Vladimirov B, Sarafian V, Nabavi SM, Atanasov AG, Berindan-Neagoe I.

Semin Cancer Biol. 2017 Oct;46:84-106. doi: 10.1016/j.semcancer.2017.06.011. Epub 2017 Jul 1. Review.

PMID:
28676460
37.

MicroRNAs as a tool to aid stratification of colorectal cancer patients and to guide therapy.

Goblirsch M, Richtig G, Slaby O, Berindan-Neagoe I, Gerger A, Pichler M.

Pharmacogenomics. 2017 Jul;18(10):1027-1038. doi: 10.2217/pgs-2017-0004. Epub 2017 Jun 22. Review.

PMID:
28639472
38.

CRISPR/Cas9: Transcending the Reality of Genome Editing.

Chira S, Gulei D, Hajitou A, Zimta AA, Cordelier P, Berindan-Neagoe I.

Mol Ther Nucleic Acids. 2017 Jun 16;7:211-222. doi: 10.1016/j.omtn.2017.04.001. Epub 2017 Apr 8. Review.

39.

Dietary Intervention by Phytochemicals and Their Role in Modulating Coding and Non-Coding Genes in Cancer.

Budisan L, Gulei D, Zanoaga OM, Irimie AI, Sergiu C, Braicu C, Gherman CD, Berindan-Neagoe I.

Int J Mol Sci. 2017 Jun 1;18(6). pii: E1178. doi: 10.3390/ijms18061178. Review.

40.

Antibody Conjugated, Raman Tagged Hollow Gold-Silver Nanospheres for Specific Targeting and Multimodal Dark-Field/SERS/Two Photon-FLIM Imaging of CD19(+) B Lymphoblasts.

Nagy-Simon T, Tatar AS, Craciun AM, Vulpoi A, Jurj MA, Florea A, Tomuleasa C, Berindan-Neagoe I, Astilean S, Boca S.

ACS Appl Mater Interfaces. 2017 Jun 28;9(25):21155-21168. doi: 10.1021/acsami.7b05145. Epub 2017 Jun 15.

PMID:
28574250
41.

Effect of Helix aspersa extract on TNFα, NF-κB and some tumor suppressor genes in breast cancer cell line Hs578T.

El Ouar I, Braicu C, Naimi D, Irimie A, Berindan-Neagoe I.

Pharmacogn Mag. 2017 Apr-Jun;13(50):281-285. doi: 10.4103/0973-1296.204618. Epub 2017 Apr 18.

42.

N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration.

Rigoutsos I, Lee SK, Nam SY, Anfossi S, Pasculli B, Pichler M, Jing Y, Rodriguez-Aguayo C, Telonis AG, Rossi S, Ivan C, Catela Ivkovic T, Fabris L, Clark PM, Ling H, Shimizu M, Redis RS, Shah MY, Zhang X, Okugawa Y, Jung EJ, Tsirigos A, Huang L, Ferdin J, Gafà R, Spizzo R, Nicoloso MS, Paranjape AN, Shariati M, Tiron A, Yeh JJ, Teruel-Montoya R, Xiao L, Melo SA, Menter D, Jiang ZQ, Flores ER, Negrini M, Goel A, Bar-Eli M, Mani SA, Liu CG, Lopez-Berestein G, Berindan-Neagoe I, Esteller M, Kopetz S, Lanza G, Calin GA.

Genome Biol. 2017 May 24;18(1):98. doi: 10.1186/s13059-017-1224-0.

43.

The "good-cop bad-cop" TGF-beta role in breast cancer modulated by non-coding RNAs.

Gulei D, Mehterov N, Ling H, Stanta G, Braicu C, Berindan-Neagoe I.

Biochim Biophys Acta. 2017 Jul;1861(7):1661-1675. doi: 10.1016/j.bbagen.2017.04.007. Epub 2017 Apr 11. Review.

PMID:
28411077
44.

Non-coding RNAs, the Trojan horse in two-way communication between tumor and stroma in colorectal and hepatocellular carcinoma.

Cătană CS, Pichler M, Giannelli G, Mader RM, Berindan-Neagoe I.

Oncotarget. 2017 Apr 25;8(17):29519-29534. doi: 10.18632/oncotarget.15706. Review.

45.

Novel Palladium(II) Complexes that Influence Prominin-1/CD133 Expression and Stem Cell Factor Release in Tumor Cells.

Fischer-Fodor E, Mikláš R, Rišiaňová L, Cenariu M, Grosu IG, Virag P, Perde-Schrepler M, Tomuleasa C, Berindan-Neagoe I, Devínsky F, Miklášová N.

Molecules. 2017 Mar 30;22(4). pii: E561. doi: 10.3390/molecules22040561.

46.

How to Diagnose and Treat a Cancer of Unknown Primary Site.

Tomuleasa C, Zaharie F, Muresan MS, Pop L, Fekete Z, Dima D, Frinc I, Trifa A, Berce C, Jurj A, Berindan-Neagoe I, Zdrenghea M.

J Gastrointestin Liver Dis. 2017 Mar;26(1):69-79. doi: 10.15403/jgld.2014.1121.261.haz. Review.

47.

Antiproliferative and Apoptotic Effects of Lidocaine on Human Hepatocarcinoma Cells. A preliminary study.

Jurj A, Tomuleasa C, Tat TT, Berindan-Neagoe I, Vesa SV, Ionescu DC.

J Gastrointestin Liver Dis. 2017 Mar;26(1):45-50. doi: 10.15403/jgld.2014.1121.261.juj.

48.

Seroprevalence of Bartonella species, Coxiella burnetii and Toxoplasma gondii among patients with hematological malignancies: A pilot study in Romania.

Messinger CJ, Gurzau ES, Breitschwerdt EB, Tomuleasa CI, Trufan SJ, Flonta MM, Maggi RG, Berindan-Neagoe I, Rabinowitz PM.

Zoonoses Public Health. 2017 Sep;64(6):485-490. doi: 10.1111/zph.12353. Epub 2017 Mar 22.

PMID:
28328183
49.

Fibroblast dynamics as an in vitro screening platform for anti-fibrotic drugs in primary myelofibrosis.

Tomuleasa C, Selicean S, Gafencu G, Petrushev B, Pop L, Berce C, Jurj A, Trifa A, Rosu AM, Pasca S, Magdo L, Zdrenghea M, Dima D, Tanase A, Frinc I, Bojan A, Berindan-Neagoe I, Ghiaur G, Ciurea SO.

J Cell Physiol. 2018 Jan;233(1):422-433. doi: 10.1002/jcp.25902. Epub 2017 May 23.

PMID:
28294327
50.

The use of rotation to fentanyl in cancer-related pain.

Dima D, Tomuleasa C, Frinc I, Pasca S, Magdo L, Berindan-Neagoe I, Muresan M, Lisencu C, Irimie A, Zdrenghea M.

J Pain Res. 2017 Feb 9;10:341-348. doi: 10.2147/JPR.S121920. eCollection 2017.

Supplemental Content

Loading ...
Support Center